Lipid Parameters are Independently Associated with Cardio–Ankle Vascular Index (CAVI) in Healthy Japanese Subjects

Daiji Nagayama1,2, Yasuhiro Watanabe2, Atsuhito Saiki2, Kohji Shirai3 and Ichiro Tatsuno2

1 Center of Diabetes and Metabolism, Shin-Oyama City Hospital, Tochigi, Japan
2 Center of Diabetes, Endocrinology and Metabolism, Toho University, Sakura Medical Center, Chiba, Japan
3 Department of Internal Medicine, Mihama Hospital, Chiba, Japan

Aim: To investigate the associations of conventional lipid parameters with arterial stiffness assessed by cardio–ankle vascular index (CAVI).

Methods: A retrospective cross-sectional study was conducted in 23,257 healthy Japanese subjects (12,729 men and 10,528 women, aged 47.1 ± 12.5 years, body mass index (BMI) 22.9 ± 3.4 kg/m²) who underwent health screening between 2004 and 2006 in Japan.

Results: Male subjects had significantly higher BMI, CAVI and triglycerides (TG), and lower high-density lipoprotein cholesterol (HDL-C) compared to female subjects. After adjusting for confounders, including gender, age, systolic blood pressure and BMI identified by multiple regression analysis, adjusted CAVI was lower in normolipidemic than in dyslipidemic subjects. Among dyslipidemic subjects, those with hypertriglyceridemia had higher adjusted CAVI. A trend test detected linear relations between adjusted CAVI and all the conventional lipid parameters throughout the entire range of serum levels. After adjusting for confounders, logistic regression models showed that all lipid parameters contributed independently to high CAVI (≥90th percentile). Receiver–operating–characteristic analysis determined reliable cut-off values of 93 mg/dl for TG (area under the curve, AUC = 0.735), 114 mg/dl for low-density lipoprotein cholesterol (AUC = 0.614) and 63 mg/dl for HDL-C (AUC = 0.728) in predicting high CAVI. These cut-off values were confirmed to independently predict high CAVI in a bivariate logistic regression model.

Conclusion: The present study demonstrated independent contribution of conventional lipid parameters to CAVI, indicating a possible association of lipid parameters with early vascular damage.

Key words: Lipid, Cardio-ankle vascular index (CAVI), Arterial stiffness

Introduction

Dyslipidemia is characterized by elevated triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) as well as decreased high-density lipoprotein cholesterol (HDL-C) levels, and has been recognized as an independent risk for cardiovascular diseases (CVD). Moreover, it is common knowledge that atherogenesis is accelerated in patients with dyslipidemia compared to that of the healthy general population. Dyslipidemia is characterized by elevated triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) as well as decreased high-density lipoprotein cholesterol (HDL-C) levels, and has been recognized as an independent risk for cardiovascular diseases (CVD). Moreover, it is common knowledge that atherogenesis is accelerated in patients with dyslipidemia compared to that of the healthy general population. From the perspective of prevention and treatment of CVD, LDL-C level of 140 mg/dl is proposed to be the reference value when screening Japanese individuals for hyper-LDL cholesterolemia. Furthermore, targeting a TG level <150 mg/dl and an HDL-C level ≥40 mg/dl is recommended. The progression of atherosclerosis may be decelerated, stopped or even reversed by intensive treatment targeting the main cardiovascular risk factors, primarily dyslipidemia. On the other hand, even if adequate control of dyslipidemia is achieved, residual cardiovascular risk is not completely eliminated, suggesting that achieving the current target lipid levels is inadequate. Additionally, the pathophysiological relationship between the vascular composition and individual lipid parameters have not been clarified.
In the management of CVD risks, early detection of atherosclerosis using simple, quantitative and non-invasive assessments is needed to initiate early treatment and prevent further complications and cardiovascular events. Several studies have reported that increased arterial stiffness is associated with increased morbidity and mortality of CVD. Cardio-ankle vascular index (CAVI) determination is a non-invasive method for detecting preclinical condition of systemic arterial stiffness. CAVI has been reported to be essentially independent of blood pressure (BP) and based on a stiffness parameter beta. This parameter has adequate reproducibility for clinical use and is associated with a number of risk factors and severity of CVD. CAVI has also been reported to be an independent predictor of major adverse cardiovascular events. These reports suggest that analyzing arterial stiffness based on CAVI may be helpful for identifying subjects with greater cardiovascular risks.

Some of the traditional arterial stiffness markers except CAVI were reported to be associated with dyslipidemia. However, in most of them, just linear correlations between lipid profiles and arterial stiffness were observed. In fact, none is established as the threshold of each lipid parameter for change in arterial stiffness. On these premises, the primary aim of this cross-sectional study was to investigate the highly-detailed relationship of the lipid profile with arterial stiffness assessed by CAVI in healthy Japanese subjects. Furthermore, we also attempted to explore the thresholds of individual lipid parameters for change in CAVI.

**Subjects and Methods**

**Design**

This retrospective cross-sectional study was approved by the Institutional Review Board and Ethics Committee of the Sakura Hospital, School of Medicine, Toho University (No. S17013). Written informed consent was obtained from the participants.

**Data Collection and Laboratory Assay Methods**

The population-based sample used in the present analysis comprised 23,257 healthy Japanese subjects residing in the major cities nationwide, who were not taking any medication and had no history of heart disease, hypertension, stroke, diabetes, nephritis or gout. They participated in the CVD and cancer screening program organized by the Japan Health Promotion Foundation between 2004 and 2006. Participants were volunteers who were not paid and were not recruited for this study as in the case of a clinical trial.

Obesity was defined as body mass index (BMI) ≥25 kg/m², according to the Examination Committee of Criteria for Obesity Disease in Japan. Blood was collected from the antecubital vein in the morning after 12-h fasting to determine glutamate-oxaloacetate transaminase (GOT), glutamate-pyruvate transaminase (GPT), γ-glutamyltranspeptidase (γ-GTP), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), TG, HDL-C and creatinine. All the blood levels were measured according to standard procedures. Non-HDL-C was defined as the difference in level between total cholesterol and HDL-cholesterol, LDL-C was calculated using Friedewald’s formula: LDL-C = (TC – (HDL-C) – (TG/5). This formula is not valid for patients with TG ≥400 mg/dl. Therefore, subjects with TG ≥400 mg/dl (N=361, 1.55%) were excluded from the analysis of LDL-C only. HbA1c (%) measured by the Japan Diabetes Society (JDC) method was converted to NGSP value (%) using the following formula: HbA1c (NGSP) (%) = HbA1c (JDS) (%) + 0.4%.

Exclusion criteria were current medication use and a history of cardiovascular disease, hypertension, stroke, diabetes and nephritis. However, one or more cardiovascular risk factors such as dyslipidemia, hypertension and glucose tolerance were newly detected in some participants.

**Measurement of CAVI and BP**

CAVI was obtained by measuring BP and pulse wave velocity (PWV) according to the following formula: CAVI = a{(2P/ΔP) × ln(Ps/Pd)PWV2} + b, where Ps is systolic BP, Pd is diastolic BP, ΔP is Ps – Pd, ρ is blood density, and a and b are constants. CAVI originates from the stiffness parameter β = ln(Ps/Pd) × (D/ΔD). D/ΔD is calculated from PWV of some length of the artery and ΔP in place of diameter change (D/ΔD). As for the application of BP of the upper brachial artery in the calculation of the CAVI equation, there is an assumption that BP at the upper brachial artery is nearly the mean of the BP from the origin of the aorta to the tibial artery at the ankle. Therefore, in cases where the BP at the aorta and the femoral artery were remarkably changed, such as in the case of femoral arterial arteriosclerosis obliterans (ABI < 0.9), the CAVI value is invalid. Also, it is wrong to measure CAVI in the standing position. In this case, BP at the ankle and brachial artery is quite different. The details of CAVI and the measurement have been described previously.

In the present study, CAVI was measured using a VaSera VS-1000 (Fukuda Denshi Co Ltd, Tokyo, Japan). Cuffs were applied to bilateral upper arms and ankles, with the subject lying supine and the head held in midline position. After resting for 10 min, the exami-
Correlation of Lipid Parameters with CAVI

Table 1. Clinical and biochemical characteristics of male and female participants

| Variable              | All          | Male         | Female        | P value* |
|-----------------------|--------------|--------------|---------------|----------|
| Number of subjects    | 23,257       | 12,729       | 10,528        | -        |
| Age (years)           | 47.1 ± 12.5  | 47.0 ± 13.0  | 47.1 ± 12.0   | 0.692    |
| Height (cm)           | 163 ± 9      | 162 ± 6      | 156 ± 6       | <0.001   |
| Body weight (kg)      | 61.6 ± 12.2  | 68.4 ± 10.5  | 53.3 ± 8.4    | <0.001   |
| BMI (kg/m²)           | 22.9 ± 3.4   | 23.9 ± 3.2   | 21.7 ± 3.3    | 0.003    |
| CAVI                  | 7.84 ± 1.07  | 7.96 ± 1.14  | 7.69 ± 0.97   | <0.001   |
| sBP (mmHg)            | 124 ± 16     | 124 ± 16     | 123 ± 16      | <0.001   |
| dBP (mmHg)            | 76 ± 12      | 76 ± 12      | 75 ± 11       | <0.001   |
| GOT (IU/l)            | 43 ± 56      | 43 ± 52      | 44 ± 60       | 0.415    |
| GPT (IU/l)            | 91 ± 18      | 91 ± 18      | 91 ± 18       | 0.465    |
| y-GTP (IU/l)          | 5.3 ± 0.6    | 5.3 ± 0.6    | 5.3 ± 0.6     | 0.086    |
| TC (mg/dl)            | 209 ± 37     | 210 ± 37     | 208 ± 36      | 0.002    |
| TG (mg/dl)            | 113 ± 95     | 117 ± 100    | 108 ± 89      | <0.001   |
| Loge TG               | 4.53 ± 0.60  | 4.55 ± 0.60  | 4.50 ± 0.59   | <0.001   |
| HDL-C (mg/dl)         | 66 ± 19      | 65 ± 18      | 67 ± 19       | <0.001   |
| LDL-C (mg/dl)         | 121 ± 34     | 122 ± 34     | 120 ± 33      | <0.001   |
| Non-HDL-C (mg/dl)     | 144 ± 39     | 145 ± 39     | 142 ± 38      | <0.001   |
| Creatinine (mg/dl)    | 0.71 ± 0.15  | 0.80 ± 0.13  | 0.62 ± 0.10   | 0.055    |

Data are presented as mean ± standard deviation. *Student’s t-test was used to compare male and female subjects.

Results

Clinical and Biochemical Characteristics of Male and Female Participants

In this study, a total of 23,257 Japanese urban residents (12,729 men and 10,528 women) aged from 20 to 74 (mean 47.1 ± 12.5) years were screened. Table 1 compares the clinical characteristics of male

Statistical Analysis

All data are expressed as mean ± standard deviation (SD). The IBM SPSS software (version 11.5, Chicago, IL, USA) was used for statistical processing. Student’s t-test or Fisher’s exact test was performed to examine gender difference in clinical variables or prevalence of major cardiovascular risks. The relationship between CAVI and clinical variables was analyzed using multiple regression analysis, and the results were used to adjust CAVI in subsequent analyses. The relationship of CAVI with each lipid parameter was analyzed using ANOVA after adjusting for confounders of CAVI, followed by trend analysis. Logistic regression analysis was used to identify contributors to high CAVI (≥90th percentile) and expressed as odds ratio (OR) with 95% confidence interval (CI). Sensitivity and specificity with respect to high CAVI were analyzed using conventional receiver–operating–characteristic (ROC) curves. In all comparisons, P values less than 0.05 were considered statistically significant.
regression analysis of the correlation of CAVI with clinical variables. GOT and GPT were omitted because of intraclass correlation with \( \text{GTP} \). TG was also omitted because of intraclass correlation with HDL-C, and non-HDL-C was added instead. Age was a major independent predictor of CAVI (\( \beta \) coefficient 0.584, \( P < 0.001 \)). Additionally, a weak correlation between CAVI and male gender (\( \beta = 0.149, P < 0.001 \)), BMI (\( \beta = -0.119, P < 0.001 \)), sBP (\( \beta = 0.139, P < 0.001 \)) or HDL-C (\( \beta = 0.107, P < 0.001 \)) was observed. These confounders, except HDL-C, were used to adjust CAVI in subsequent analyses as shown in Fig. 1 and 2.

### Comparison of Adjusted CAVI between Types of Dyslipidemia

We classified the participants into four groups according to the presence of hypertriglyceridemia and/or hyper-LDL cholesterol. Fig. 1 compares adjusted CAVI between normolipidemic and dyslipidemic subjects. Adjusted CAVI was lower in normolipidemic subjects compared to all three groups of dyslipidemic

---

**Table 2.** Prevalence of major cardiovascular risk factors

| Variable                        | All     | Male    | Female  | \( P \) value ** |
|---------------------------------|---------|---------|---------|-----------------|
| Older age (Age \( \geq 65 \))   | 9.2%    | 9.2%    | 6.6%    | <0.001          |
| Obesity (BMI \( \geq 25 \))     | 24.9%   | 32.9%   | 15.4%   | <0.001          |
| Hypertension (BP \( \geq 140/90 \)) | 15.3%  | 16.1%   | 14.3%   | <0.001          |
| IFG (FPG \( \geq 110 \))        | 10.1%   | 10.2%   | 10.0%   | 0.498           |
| Hypo-HDL cholesterolemia (HDL-C \( < 40 \)) | 5.0%  | 5.3%    | 4.7%    | 0.058           |
| Hypertriglyceridemia (TG \( \geq 150 \)) | 24.8%  | 25.9%   | 23.5%   | <0.001          |
| Hyper-LDL cholesterolemia (LDL-C \( \geq 140 \)) | 20.1%  | 21.6%   | 18.3%   | <0.001          |

**Table 3.** Correlation of CAVI with clinical variables analyzed by multiple regression model

| Variable           | \( \beta \) coefficient | SE     | \( P \) value |
|--------------------|-------------------------|--------|--------------|
| Male               | 0.149                   | 0.125  | <0.001       |
| Age                | 0.584                   | 0.017  | <0.001       |
| BMI                | -0.119                  | 0.003  | <0.001       |
| sBP                | 0.139                   | 17.105 | <0.001       |
| \( \gamma \)-GTP   | 0.004                   | 0.538  | <0.001       |
| HbA1c              | -0.003                  | 0.015  | 0.712        |
| HDL-C              | -0.181                  | 0.001  | <0.001       |
| Non-HDL-C          | 0.107                   | <0.001 | 0.542        |
| Creatinine         | 0.012                   | 1.470  | 0.142        |

\( \beta \) coefficient: 0.584, \( P < 0.001 \).

---

and female participants. Compared with women, men had significantly and markedly higher BMI and CAVI (7.96 ± 1.14 vs. 7.69 ± 0.97, \( P < 0.001 \)). Furthermore, slightly higher TG and lower HDL-C were observed in male subjects.

### Prevalence of Major Cardiovascular Risk Factors

The prevalence of conventional cardiovascular risks in participants is shown in Table 2. The proportions of older age (defined as age \( \geq 65 \) years), obesity (defined as BMI \( \geq 25 \) kg/m\(^2\)), hypertension, hypertriglyceridemia (defined as TG \( \geq 150 \) mg/dl) and hyper-LDL cholesterolemia (defined as LDL-C \( \geq 140 \) mg/dl) were significantly higher in men than in women, whereas those of IFG and hypo-HDL cholesterolemia (defined as HDL-C \( < 40 \) mg/dl) were not different.

### Correlation of CAVI with Clinical Variables Analyzed by Multiple Regression Model

Next, we examined the factors associated with CAVI. Table 3 summarizes the results of a multiple regression analysis of the correlation of CAVI with clinical variables. GOT and GPT were omitted because of intraclass correlation with \( \text{GTP} \). TG was also omitted because of intraclass correlation with HDL-C, and non-HDL-C was added instead. Age was a major independent predictor of CAVI (\( \beta \) coefficient = 0.584, \( P < 0.001 \)). Additionally, a weak correlation between CAVI and male gender (\( \beta = 0.149, P < 0.001 \)), BMI (\( \beta = -0.119, P < 0.001 \)), sBP (\( \beta = 0.139, P < 0.001 \)) or HDL-C (\( \beta = 0.107, P < 0.001 \)) was observed. These confounders, except HDL-C, were used to adjust CAVI in subsequent analyses as shown in Fig. 1 and 2.
subjects. Among subjects with hyper-LDL cholesterol, those with concurrent hypertriglyceridemia had higher adjusted CAVI.

**Relationship between Adjusted CAVI and Lipid Parameters**

Fig. 2 shows the relationship of adjusted CAVI with serum level profiles of TC, TG, HDL-C, non-HDL-C and LDL-C. A trend test after ANOVA detected a positive linear relationship of adjusted CAVI with TC, TG, non-HDL-C or LDL-C, and a negative relationship with HDL-C for the entire range of serum levels. In addition, trend tests yielded relatively large variances for TG ($F=196.11$), HDL-C ($F=329.27$) and non-HDL-C ($F=191.18$).

**Odds Ratios for High CAVI (≥ 90th Percentile) Per 1-SD Increment of Lipid Parameters Analyzed by Logistic Regression Models**

Furthermore, we examined the contribution of each lipid parameter to high CAVI in all participants using multivariate logistic regression models (Table 4). High CAVI was conveniently defined as higher than or equal to the 90th percentile of CAVI (≥ 9.40 in males, ≥ 9.00 in females) because CAVI above 9 corresponds substantially to the cut-off value for the presence of coronary artery stenosis.\(^{20}\)

ORs for high CAVI per 1-SD increment were calculated using the actual serum levels of individual lipid parameters (continuous model). Only TG was converted to logarithmic scale to curb departure from normality.

After adjusting for dichotomous confounders including gender, older age, obesity, hypertension and IFG, the ORs (95% CI) of high CAVI were 1.24 (1.19 – 1.31) for TC, 1.90 (1.81 – 1.99) for Log e TG, 0.444 (0.417 – 0.472) for HDL-C, 1.63 (1.55 – 1.70) for non-HDL-C and 1.30 (1.24 – 1.37) for LDL-C.

**Discriminatory Powers of Lipid Parameters for High CAVI**

The ROC curves and Youden’s J Index, which represents the maximum of sensitivity + specificity – 1 for all cutoff points in the ROC curve, were generated to evaluate the discriminatory powers and cut-off values of lipid parameters for high CAVI (Fig. 3). The diagnostic accuracy of each lipid parameter (area under curve, 95% CIs) for high CAVI was 0.591 (0.579 – 0.603) for TC, 0.735 (0.725 – 0.745) for TG, 0.728 (0.718 – 0.738) for HDL-C, 0.692 (0.682 – 0.702) for non-HDL-C, and 0.614 (0.602 – 0.625) for LDL-C. Additionally, ROC curve analysis identified the cut-off values of lipid parameters in predicting high CAVI as follows: 209 mg/dl for TC, 93 mg/dl for TG, 63 mg/dl for HDL-C, 143 mg/dl for non-HDL-C, and 114 mg/dl for LDL-C (Table 5).

**Bivariate Logistic Regression Model for Factors Predicting High CAVI (≥ 90th Percentile)**

Furthermore, we examined the factors associated
with high CAVI using multivariate logistic regression analysis with dichotomous variables (Table 6). Gender and major cardiovascular risks were entered into the model as identified in Table 2. TG, HDL-C and LDL-C were adopted using binary cut-off thresholds identified in the analysis shown in Table 5. Because we adopted LDL-C that was calculated using Friedewald’s formula in this model, subjects with TG ≥400 mg/dl (N=361, 1.55%) were excluded.

The analysis identified the following variables to be positively associated with high CAVI: male gender (OR, 95% CI: 2.25, 2.01–2.53), older age (12.7, 11.3–14.4), hypertension (1.85, 1.63–2.09), TG ≥93 mg/dl (2.43, 2.14–2.75), HDL-C <63 mg/dl (2.60, 2.29–2.94), and LDL-C ≥114 mg/dl (1.48, 1.32–1.67). Interestingly, obesity correlated negatively with high CAVI (OR: 0.817, 95% CI: 0.723–0.924). IFG was not a significant independent predictor of high CAVI.

Discussion

This cross-sectional study in 23,257 healthy mid-
observed linearly from the lowest to the highest serum levels for all lipid parameters. Accordingly, the lowest levels of TC, TG, non-HDL-C and LDL-C, and the highest level of HDL-C would reflect the most desirable state of arterial stiffness expressed as the lowest CAVI, at least in this study population. Furthermore, cut-off values of TC, TG, non-HDL-C and LDL-C for predicting high CAVI were lower, and that of HDL-C was higher compared to current targets of lipid levels for primary prevention of CVD in Japan.

Table 4. Odds ratios [95% confidence intervals (CIs)] for high CAVI (≥90th percentile) per 1-SD increment of each lipid parameter analyzed by logistic regression models

| Parameters   | OR   | 95% CI          | P value |
|--------------|------|-----------------|---------|
| TC           | 1.24 | 1.19–1.31       | <0.001  |
| Log_ T G     | 1.90 | 1.81–1.99       | <0.001  |
| HDL-C        | 0.444 | 0.417–0.472    | <0.001  |
| Non-HDL-C    | 1.63 | 1.55–1.70       | <0.001  |
| LDL-C        | 1.30 | 1.24–1.37       | <0.001  |

The actual values of lipid parameters were entered as continuous variables to calculate ORs per 1-SD increment of lipid parameters adjusted for gender, older age, obesity, hypertension and IFG. SD, standard deviation; CAVI, cardio-ankle vascular index; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; IFG, impaired fasting glucose.

Atherogenic dyslipidemia, which refers to the condition of hypertriglyceridemia combined with hypo-HDL cholesterolemia, has emerged as an important risk factor for CVD, along with hyper-LDL cholesterolemia. However, a lack of correlation between individual lipid parameters and existing arterial stiffness markers such as PWV and augmentation index has been noted in previous studies, indicating that these traditional lipid parameters may not be robust enough to predict CVD risk in individuals. Recently, many studies have suggested that analyzing the structure and function of apolipoproteins is imperative in the management of atherosclerosis-related diseases. In contrast, our population-based study clearly demonstrated the relationship between CAVI and individual lipid parameters. Therefore, as shown in the present study, conventional lipid parameters may now be used reliably to manage vascular health.

Increase or decrease in adjusted CAVI was observed linearly from the lowest to the highest serum levels for all lipid parameters. Accordingly, the lowest levels of TC, TG, non-HDL-C and LDL-C, and the highest level of HDL-C would reflect the most desirable state of arterial stiffness expressed as the lowest CAVI, at least in this study population. Furthermore, cut-off values of TC, TG, non-HDL-C and LDL-C for predicting high CAVI were lower, and that of HDL-C was higher compared to current targets of lipid levels for primary prevention of CVD in Japan.
Agents such as pitavastatin\textsuperscript{45} and ezetimibe\textsuperscript{46} have been reported to improve endothelial function as assessed by flow-mediated dilation\textsuperscript{62, 63}. In addition, Satoh\textsuperscript{64} reported that eicosapentaenoic acid, an n-3 polyunsaturated fatty acid that lowers TG, decreases CAVI. The pathological processes in the early phase of atherogenesis are initiated by accumulation of modified forms of LDL, followed by cellular infiltration and foam cell formation\textsuperscript{47}. Furthermore, we have reported that CAVI may be a marker related to endothelial function in subjects with coronary artery disease\textsuperscript{59}. Together, these findings suggest that CAVI may reflect endothelial dysfunction associated with increased serum LDL-C, as shown in this study.

A study has suggested that elevated serum TG and decreased HDL-C are secondary to resistance to insulin-stimulated glucose uptake\textsuperscript{49}. Furthermore, inflammation and oxidative stress involved in insulin resistance play a central role in its pathogenesis. We have reported that high CAVI may reflect insulin resistance and can be decreased by insulin-sensitizing therapeutic approaches\textsuperscript{50-53}. Additionally, Satoh \textit{et al.}\textsuperscript{42} have reported that the severity of metabolic syndrome correlates positively with CAVI, probably due to insulin resistance. Therefore, both TG and HDL-C are considered to be surrogate markers to help detect insulin resistance. However, they are also mediators associated with inflammation and atherosclerosis in metabolic syndrome. HDL appears to act as a vasoprotective mediator, and is recognized for its ability to shuttle excess cholesterol from peripheral tissues to the liver for excretion in the process of reverse cholesterol transport, likely contributing to the well-known inverse relationship between HDL-C and CVD. Additional cardioprotective roles of HDL have been identified, including anti-inflammatory, antioxidative and anti-apoptotic properties in vascular endothelial cells\textsuperscript{54-56}. The inverse relationship of CAVI with serum HDL-C shown in this study may reflect the favorable effect of HDL on arterial stiffness. In contrast, there is no evidence supporting the hypothesis that TG per se is a culprit in the atherogenic process. However, recently published works have confirmed that TG-rich lipoproteins and their remnants seen in metabolic syndrome are also predictors of arterial stiffening evaluated by CAVI and intima-media thickness\textsuperscript{37, 58}. Remnant cholesterol can be taken up into the subendothelial space by scavenger receptors of resident macrophages, thus promoting foam cell formation\textsuperscript{59}. In fact, many studies have shown that TG-lowering medications exert vasoprotective effects. Fibrate is a widely used class of lipid-regulating agents that affects lipoprotein metabolism, attenuates postprandial lipemia and reduces TG-rich lipoprotein\textsuperscript{50, 61}. Fibrate was reported to improve endothelial function as assessed by flow-mediated dilation\textsuperscript{62, 63}. In addition, Satoh \textit{et al.}\textsuperscript{64} have reported that eicosapentaenoic acid, an n-3 polyunsaturated fatty acid that lowers TG, decreases CAVI accompanied by decreases in TG and oxidized LDL. On the other hand, our finding may support the notion of “lower is better” for serum TG with respect to the relationship with arterial stiffness. Consequently,
more intensive TG-lowering therapy may be appropriate, although it remains controversial whether adherence to the current guideline for hypertriglyceridemia contributes to CVD prevention.

In 2002, brachial–ankle PWV (baPWV) was proposed to be a marker of vascular damage and was reported to be a predictive marker of CVD. Furthermore, baPWV correlates strongly with arterial stiffness, and is proposed as the gold standard method by the European Society of Hypertension/European Society of Cardiology guidelines. However, PWV, unlike CAVI, is known to strongly depend on BP at the time of measurement, and to have inadequate reproducibility. When the selective β1-blocker metoprolol was administered to Japanese men, systolic and diastolic BP decreased for 6 h. During this time, baPWV significantly decreased, whereas CAVI did not change. This phenomenon could be explained as follows: CAVI does not change because metoprolol does not affect the contracture of arterial wall smooth muscle cells, whereas baPWV decreases because PWV has the property to decrease according to a decrease in BP. Therefore, the validity of PWV in reflecting actual arterial stiffness is controversial, and this parameter is unsuitable for evaluating the effect of antihypertensive drugs on the arterial wall. On the other hand, unlike PWV, CAVI is not affected by BP at the time of measurement, which makes it more precise and reproducible than PWV as an index of arterial stiffness, although its predictive value of cardiovascular events has not been established adequately. Moreover, a multiple regression analysis revealed that CAVI was superior to baPWV as a predictor of carotid and coronary arteriosclerosis.

The inverse relationship of CAVI with BMI shown in this report (Tables 3 and 6) may seem inconsistent with previous reports showing that CAVI increases reversibly according to abdominal obesity/metabolic syndrome. We previously reported a negative relationship between CAVI and BMI in healthy middle-aged Japanese subjects, suggesting that the systemic accumulation of adipose tissue per se may lead to a linear decrease of arterial stiffness in nonobese and obese subjects without metabolic disorders. If the study was conducted in obese subjects with metabolic disorders, the results might have been markedly different. We speculate that adipose tissue-derived cytokines may explain the paradox in arterial stiffness observed in the present study. Shiba et al. reported that intravitreal injection of antivascular endothelial growth factor (anti-VEGF) drugs decreased CAVI and carotid intima–media thickness, probably due to decreased vasa vasorum flow and improved kidney function. Inhibition of angiogenesis inducers such as VEGF may therefore result in a decrease in arterial stiffness. On the other hand, tenomodulin (TNMD), a putative angiogenesis inhibitor, has been shown to be highly expressed in human adipose tissue, especially in obese subjects. Furthermore, a recent study suggests that TNMD acts as a protective factor in visceral adipose tissue to alleviate insulin resistance in obesity. We have previously reported that improved insulin resistance may contribute to decreased CAVI in obese and type 2 diabetic patients. These reports suggest that adipose tissue may affect systemic vascular function through expression of antiangiogenic factors such as TNMD. For the metabolically healthy overweight/obese individuals only, these various protective cytokines and neuroendocrine profiles may contribute to a decrease in arterial stiffness. Further elucidation of the cause–effect relationship between accumulation of adipose tissue and regulation of arterial pathophysiology is required.

Table 6. Bivariate logistic regression model for high CAVI (≥90th percentile)

| Variable                          | OR   | 95% CI          | P value |
|----------------------------------|------|-----------------|---------|
| Gender (Male: 1, Female: 0)      | 2.25 | 2.01–2.53       | <0.001  |
| Older age (Age ≥65: 1, <65: 0)   | 12.7 | 11.3–14.4       | <0.001  |
| Obesity (BMI ≥25: 1, <25: 0)     | 0.817| 0.723–0.924     | <0.001  |
| Hypertension (+: 1, –: 0)        | 1.85 | 1.63–2.09       | <0.001  |
| IFG (FPG ≥110: 1, <110: 0)       | 0.921| 0.820–1.03      | 0.158   |
| TG ≥93 mg/dl                     | 2.43 | 2.14–2.75       | <0.001  |
| HDL-C <63 mg/dl                  | 2.60 | 2.29–2.94       | <0.001  |
| LDL-C ≥114 mg/dl                 | 1.48 | 1.32–1.67       | <0.001  |

Akaike’s Information Criterion: 9940.6, residual deviance: 9922.6. Subjects with TG ≥400 mg/dl (N = 361, 1.55%) were excluded.

OR, odds ratio; CI, confidence interval; CAVI, cardio-ankle vascular index; IFG, Impaired fasting glucose; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol.
The limitations of this study include the lack of data on some potential confounders such as proteinuria, alcohol consumption, menopause, and smoking status. In addition, the cross-sectional nature of this study does not allow determination of the time course for the causal relationship between lipid profiles and the risk of arterial stiffness. Therefore, it was not possible to establish the exact pathophysiology linking each lipid parameter with CAVI. From these viewpoints, longitudinal cohort studies are needed to clarify the change in relationship between lipid parameters and arterial stiffness during the evolution of cardiovascular risks.

**Conclusion**

The present study demonstrated the independent contribution of conventional lipid parameters to CAVI, indicating a possible association of lipid parameters with early vascular damage.

**Declaration of Conflicting Interests**

The author(s) declare no conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Acknowledgment**

We are grateful to Dr. Kenji Suzuki, Japan Health Promotion Foundation, for his enormous contribution to this study, and we gratefully acknowledge the investigators, coinvestigators, study coordinators, and patients who participated in this study.

**Author Contributions**

Concept/design: Kohji Shirai  
Data analysis, interpretation: Daiji Nagayama  
Critical revision of article: Ichiro Tatsuno  
Data interpretation: Yasuhiro Watanabe, Atsuhito Saiki

**References**

1) Milionis HJ, Elisafo MS, Mikhailidis DP: Lipid abnormalities and cardiovascular risk in the elderly. Curr Med Res Opin, 2008, 24: 653-657
2) Hosseini-Esfahani F, Mousavi Nasl Khameneh A, Mirmiran P, Ghanbarian A, Azizi F: Trends in risk factors for cardiovascular disease among Iranian adolescents: the Tehran Lipid and Glucose Study. J Epidemiol, 2011; 21: 319-328
3) De Freitas EV, Brandão AA, Pozzan R, Magalhães ME, Fonseca F, Pizzi O, Campana E, Brandão AP: Importance of high-density lipoprotein-cholesterol (HDL-C) levels to the incidence of cardiovascular disease (CVD) in the elderly. Arch Gerontol Geriatr, 2011, 52: 217-222
4) Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, De Backer G, Joussilvah P, Keil U, Thomesen T, Whincup P, Graham IM, investigators S: HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis, 2009; 206: 611-616
5) Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation, 2007; 115: 450-458
6) Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbis R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS): ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011; 217: 3-46
7) Teramoto T, Sasaki S, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society: Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb, 2013; 20: 517-523
8) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Collaborators CTTC: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 9,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278
9) Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22
10) Yokoyama M, Origa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Okawa S, Sasaki J, Hishida H, Iitaka H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098
11) Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C: Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J, 2010; 31: 1865-1871
12) Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ: Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation, 2010; 121: 505-511
13) Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; car-
dioankle vascular index (CAVI). J Atheroscler Thromb, 2006; 13: 101-107
14) Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, Miyashita Y, Saiki A, Takahashi M, Suzuki K, Takata M: Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb, 2011; 18: 924-938
15) Shirai K, Saiki A, Nagayama D, Tatsuno I, Shimizu K, Shirai K: The role of monitoring arterial stiffness with cardio-ankle vascular index in the control of lifestyle-related diseases. Pulse (Basel), 2015; 3: 118-133
16) Saiki A, Sato Y, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawa H, Nagumo A, Nagayama D, Ohira M, Endo K, Tatsuno I: The role of a novel arterial stiffness parameter, cardio-ankle vascular index (CAVI), as a surrogate marker for cardiovascular diseases. J Atheroscler Thromb, 2016; 23: 155-168
17) Matsu Y, Kario K, Ishikawa J, Eguchi K, Hoshide S, Shimada K: Reproducibility of arterial stiffness indices (pulse wave velocity and augmentation index) simultaneously assessed by automated pulse wave analysis and their associated risk factors in essential hypertensive patients. Hypertens Res, 2004; 27: 851-857
18) Yambe T, Yoshizawa M, Saijo Y, Yamaguchi T, Shibata M, Konno S, Nitta S, Kuwayama T: Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother, 2004; 58: 95-98
19) Kubozono T, Miyata M, Ueyama K, Nagaki A, Otsuji Y, Kusano K, Kubozono O, Tei C: Clinical significance and reproducibility of new arterial distensibility index. Circ J, 2007; 71: 89-94
20) Nakamura K, Tomaru T, Yamamato S, Miyashita Y, Shirai K, Noike H: Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J. 2008; 72: 598-604
21) Noike H, Nakamura K, Sugiyama Y, Iizuka T, Shimizu K, Takahashi M, Hirano K, Suzuki M, Mikamo H, Nakagami T, Shirai K: Changes in cardioankle vascular index in smoking cessation. J Atheroscler Thromb, 2010; 17: 517-525
22) Shimizu K, Yamamoto T, Takahashi M, Sato S, Noike H, Shirai K: Effect of nitroglycerin administration on cardio-ankle vascular index. Vasc Health Risk Manag, 2016; 12: 313-319
23) Nakamura K, Iiduka T, Takahashi M, Shimizu K, Mikamo H, Nakagami T, Suzuki M, Hirano K, Sugiyama Y, Tomaru T, Miyashita Y, Shirai K, Noike H: Association between cardioankle vascular index and serum cystatin C levels in patients with cardiovascular risk factor. J Atheroscler Thromb, 2009; 16: 371-379
24) Izuhara M, Shioji K, Kadota Y, Baba O, Takeuchi Y, Uegaito T, Matsuo S, Matsuda M: Relationship of cardiovascular index to carotid and coronary arteriosclerosis. Circ J, 2008; 72: 1762-1767
25) Miyoshi T, Doi M, Hirohata S, Sakane K, Kamikawa S, Kitawaki T, Kaji Y, Kusano KF, Ninomiya Y, Kusachi S: Cardio-ankle vascular index is independently associated with the severity of coronary atherosclerosis and left ventricular function in patients with ischemic heart disease. J Atheroscler Thromb, 2010; 17: 249-258
26) Yingchoncharoen T, Limpijankit T, Jongjirasisri S, Laothamat J, Yam Wong S, Sritara P: Arterial stiffness contributes to coronary artery disease risk prediction beyond the traditional risk score (RAMA-EGAT score). Heart Asia, 2012; 4: 77-82
27) Suzuki J, Kurosu T, Kon T, Tomaru T: Impact of cardiovascular risk factors on progression of arteriosclerosis in younger patients: evaluation by carotid duplex ultrasonography and cardio-ankle vascular index (CAVI). J Atheroscler Thromb, 2014; 21: 554-562
28) Nagayama D, Yamaguchi T, Saiki A, Imamura H, Sato Y, Ban N, Kawa H, Nagumo A, Shirai K, Tatsuno I: High serum uric acid is associated with increased cardio-ankle vascular index (CAVI) in healthy Japanese subjects: a cross-sectional study. Atherosclerosis, 2015; 239: 163-168
29) Sato Y, Nagayama D, Saiki A, Watanabe R, Watanabe Y, Imamura H, Yamaguchi T, Ban N, Kawa H, Nagumo A, Ohira M, Endo K, Kurosu T, Tomaru T, Shirai K, Tatsuno I: Cardio-ankle vascular index is independently associated with future cardiovascular events in outpatients with metabolic disorders. J Atheroscler Thromb, 2016; 23: 596-605
30) Sato-Chasana N, Cotani K, Yamakage H, Yamada T, Araki R, Okajima T, Adachi M, Oishi M, Shimatsu A; Japan Obesity and Metabolic Syndrome Study (JOMS) Group: Cardio-ankle vascular index predicts for the incidence of cardiovascular events in obese patients: a multicenter prospective cohort study (Japan Obesity and Metabolic Syndrome Study: JOMS). Atherosclerosis, 2015; 242: 461-468
31) Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity: New criteria for ‘obesity disease’ in Japan. Circ J, 2002; 66: 987-992
32) Roberts WC: The Friedewald-Levy-Fredrickson formula for calculating low-density lipoprotein cholesterol, the basis for lipid-lowering therapy. Am J Cardiol, 1988; 62: 345-346
33) The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al.: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Soc, 2010; 53: 450-467
34) Genuh S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003; 26: 3160-3167
35) Carretero OA, Oparil S: Essential hypertension. Part I: definition and etiology. Circulation, 2000; 101: 329-335
36) Youden WJ: Index for rating diagnostic tests. Cancer, 1950; 3: 32-35
37) Urbina EM, Kimball TR, Khoury PR, Daniels SR, Dolan LM: Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. J Hypertens, 2010; 28: 1692-1698
38) Gordon SM, Davidson WS, Urbina EM, Dolan LM, Heink A, Zang H, Lu LJ, Shah AS: The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth. Diabetes, 2013; 62: 2958-2967
39) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421

40) Miyashita Y, Endo K, Saiki A, Ban N, Miyashita Y, Shirai K: Increased cardiac-ankle vascular index in hyperlipidemic patients without diabetes or hypertension. J Atheroscler Thromb, 2015; 22: 272-283

41) Wang H, Liu J, Zhao H, Zhao X, Li L, Shi H, Zhan S, Liu J: Relationship between cardiac-ankle vascular index and plasma lipids in hypertension subjects. J Hum Hypertens, 2015; 29: 105-108

42) Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K: Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb, 2009; 16: 539-545

43) Miyashita Y, Endo K, Saiki A, Ban N, Nagumo A, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K: Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness. J Atheroscler Thromb, 2010; 17: 1070-1076

44) Endo K, Saiki A, Oyama T, Miyashita Y, Shirai K: Cardiac-ankle vascular index may reflect endothelial function in type 2 diabetes. Int J Clin Pract, 2011; 65: 1200-1201

45) Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988; 37: 1595-1607

46) Miyashita Y, Endo K, Saiki A, Ban N, Yamaguchi T, Kawana H, Oyama T, Miyashita Y, Shirai K: Improvement of cardiac-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract, 2010; 64: 1796-1801

47) Pentikäinen MO, Öönni K, Ala-Korpela M, Kovanen PT: Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med, 2000; 247: 359-370

48) Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988; 37: 1595-1607

49) Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Oyama T, Miyashita Y, Shirai K: Improvement of cardiac-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract, 2010; 64: 1796-1801

50) Nagayama D, Endo K, Oyama T, Yamaguchi T, Ban N, Kawa H, Nagumo A, Murano T, Shirai K, Tatsuno I: Pioglitazone improves the cardiac-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin. Diabetes Metab Syndr Obes, 2014; 7: 313-319

51) Nagayama D, Ohira M, Saiki A, Shirai K, Tatsuno I: Sarpogrelate hydrochloride decreases cardiac-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients. Int Heart J, 2014; 55: 337-341

52) Ohira M, Yamaguchi T, Saiki A, Ban N, Kawana H, Nagumo A, Murano T, Shirai K, Tatsuno I: Pioglitazone improves the cardiac-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin. Diabetes Metab Syndr Obes, 2014; 7: 313-319

53) Nagayama D, Ohira M, Saiki A, Shirai K, Tatsuno I: Sarpogrelate hydrochloride decreases cardiac-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients. Int Heart J, 2014; 55: 337-341

54) Barter PJ, Nicholls S, Rye KA, Anantharamaih GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res, 2004; 95: 764-772

55) Gordon SM, Hofmann S, Askew DS, Davidson WS: High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab, 2011; 22: 9-15

56) Sutter I, Velagapudi S, Othman A, Riwanto M, Manz J, Rohrer L, Rentsch K, Hornemann T, Landmesser U, von Eckardstein A: Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-oxidative activity of HDL. Atherosclerosis, 2015; 241: 539-546

57) Taguchi M, Ishigami M, Nishida M, Moriyama Y, Yamashita S, Yamamura T: Remnant lipoprotein-cholesterol is a predictive biomarker for large artery atherosclerosis in apparently healthy women: usefulness as a parameter for annual health examinations. Annals of Clinical Biochemistry, 2011; 48: 332-337

58) Toth PP: Triglyceride-rich lipoproteins as a causatol factor for cardiovascular disease. Vasc Health Risk Manag, 2016; 12: 171-183

59) McPherson R: Remnant cholesterol: “Non-(HDL-C + LDL-C)” as a coronary artery disease risk factor. J Am Coll Cardiol, 2013; 61: 437-439

60) Steals B, Dallongeville J, Aureux J, Schoonjans K, Leitersdorff E, Fruchart J-C: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998; 98: 2088-2093

61) Weintraub MS, Charach G, Grosskopf I: Effect of bezafibrate and metformin on postprandial lipemia. Atherosclerosis, 1998; 138: 71-75

62) Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A: Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation, 2000; 101: 1773-1779

63) Sahebkar A, Giua R, Pedone C, Ray KK, Vallejo-Vaz AJ, Costanzo L: Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res, 2016; 111: 163-179

64) Satoh N, Shimatsu A, Kotai Y, Araki K, Koyama K, Okajima T, Tanabe M, Ooishi M, Kotani K, Ogawa Y: Evaluation of the cardiac-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obese and metabolic syndrome. Hypertens Res, 2008; 31: 1921-1930

65) Miyashita Y, Endo K, Oyama T, Miyashita Y, Shirai K: Frequency of coronary artery stenosis in patients with asymptomatic familial hypercholesterolemia and its association with carotid intimal thickness and cardiac-ankle vascular index. Research Reports in Clinical Cardiology, 2017; 8: 19-20, DOI: https://doi.org/10.2147/RRCC.135981

66) Satoh N, Shimatsu A, Oishi Y, Araki K, Koyama T, Okajima T, Tanabe M, Ooishi M, Kotani K, Ogawa Y: Evaluation of the cardiac-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obese and metabolic syndrome. Hypertens Res, 2008; 31: 1921-1930

67) Miyashita Y, Endo K, Oyama T, Miyashita Y, Shirai K: Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness. J Atheroscler Thromb, 2010; 17: 1070-1076

68) Pentikäinen MO, Öönni K, Ala-Korpela M, Kovanen PT: Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med, 2000; 247: 359-370

69) Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 1988; 37: 1595-1607

70) Nagayama D, Saiki A, Endo K, Yamaguchi T, Ban N, Kawana H, Oyama T, Miyashita Y, Shirai K: Improvement of cardiac-ankle vascular index by glimepiride in type 2 diabetic patients. Int J Clin Pract, 2010; 64: 1796-1801

71) Nagayama D, Endo K, Oyama T, Yamaguchi T, Ban N, Kawa H, Nagumo A, Saiki A, Oyama T, Miyashita Y, Shirai K: Effects of body weight reduction on cardiac-ankle vascular index (CAVI). Obes Res Clin Pract, 2013; 7: e139-145
HC: Usefulness of brachial-ankle pulse wave velocity as a predictive marker of multiple coronary artery occlusive disease in Korean type 2 diabetes patients. Diabetes Res Clin Pract, 2009; 85: 30-34
66) Maeda Y, Inoguchi T, Etoh E, Kodama Y, Sasaki S1, Sonoda N, Nawata H, Shimabukuro M, Takayanagi R: Brachial-ankle pulse wave velocity predicts all-cause mortality and cardiovascular events in patients with diabetes: the Kyushu Prevention Study of Atherosclerosis. Diabetes Care, 2014; 37: 2383-2390
67) Sugawara J, Hayashi K, Yoko T, Cortez-Coope MY, DeVan AE, Anton MA, Tanaka H: Brachial-ankle pulse wave velocity: an index of central arterial stiffness? J Hum Hypertens, 2005; 19: 401-406
68) Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Hegarty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Rulope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farisga C, Gaia D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waebber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 2007; 25: 1105-1187
69) Wen W, Luo R, Tang X, Tang L, Huang HX, Wen X, Hu S, Peng B: Age related progression of arterial stiffness and its elevated positive association with blood pressure in healthy people. Atherosclerosis, 2015; 238: 147-152
70) Takaki A, Ogawa H, Wakeyama T, Iwami T, Kimura M, Hadano Y, Matsuda S, Miyazaki Y, Hiratsuka A, Matsuzaki M: Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness. Hypertens Res, 2008; 31: 1347-1355
71) Horinaka S, Yabe A, Yagi H, Ishimura K, Hara H, Iemura T, Matsuoka H: Comparison of atherosclerotic indicators between cardio ankle vascular index and brachial ankle pulse wave velocity. Angiology, 2009; 60: 468-476
72) Sairaku A, Eno S, Hondo T, Teragawa H, Nakano Y, Matsuda K, Kishita T, Kitara Y: Head-to-head comparison of the cardio-ankle vascular index between patients with acute coronary syndrome and stable angina pectoris. Hypertens Res, 2010; 33: 1162-1166
73) Nagayama D, Imamura H, Sato Y, Yamaguchi T, Ban N, Kawana H, Ohira M, Saiki A, Shirai K, Tatsuno I: Inverse relationship of cardioankle vascular index with BMI in healthy Japanese subjects: a cross-sectional study. Vasc Health Risk Manag, 2016; 13: 1-9
74) Shiba T, Takahashi M, Yoshida I, Taniguchi H, Matsu moto T, Hori Y. Arteriosclerotic changes after intravitreal injections of anti-vascular endothelial growth factor drugs in patients with exudative age-related macular degeneration. Ophthalmonologist. 2016; 235: 225-232
75) Saiki A, Olsson M, Jernås M, et al. Tenomodulin is highly expressed in adipose tissue, increased in obesity, and down-regulated during diet-induced weight loss. J Clin Endocrinol Metab. 2009; 94: 3987-3994
76) Senol-Cosar O, Flach RJ, DiStefano M, et al. Tenomodulin promotes human adipocyte differentiation and beneficial visceral adipose tissue expansion. Nat Commun. 2016; 16: 10686
77) Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, Lin CM, Chen HW, Yu KH: Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford), 2010; 49: 141-146